Q3 2025 Earnings Call Transcript November 4, 2025 Verastem, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, ...

A live webcast of the fireside chats can be accessed under “Events & Presentations” in the Investor section of the Company’s website, https://investor.verastem.com/events. A replay of the webcasts ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial ...

Joshua K. Sabari, MD, director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center, ...

The company expects to share safety and efficacy results from the RAMP-205 expansion cohort in first-line advanced pancreatic cancer and initial results from the Phase I/IIa trial evaluating VS-7375 ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. On November 4, 2025, Pasithea Therapeutics Corp announced the ...

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced ...

BackgroundSepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It ...